Venoms as Sources of Novel Anti-parasitic Agents

Adade, Camila M.; Souto-Padrón, Thaïs

doi:10.1007/978-94-007-6726-3_4-1

Cited by 7 publications

(4 citation statements)

References 133 publications

(178 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It inhibits ATP production in parasite-infected erythrocytes [ 306 ]. Finally, Phylloseptin-1, a cationic peptide from the skin secretion of Phyllomedusa azurea , demonstrates high anti-parasitic activity and prevents cross-resistance because of its distinctive chemical structure [ 307 ].…”

Section: Peptide Targeting For Leishmaniasis and Chagas Disease Thera...mentioning

confidence: 99%

The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis

Berhe,

Kumar Cinthakunta Sridhar,

Zerihun

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Chagas disease and leishmaniasis are both neglected tropical diseases that affect millions of people around the world. Leishmaniasis is currently the second most widespread vector-borne parasitic disease after malaria. The World Health Organization records approximately 0.7–1 million newly diagnosed leishmaniasis cases each year, resulting in approximately 20,000–30,000 deaths. Also, 25 million people worldwide are at risk of Chagas disease and an estimated 6 million people are infected with Trypanosoma cruzi. Pentavalent antimonials, amphotericin B, miltefosine, paromomycin, and pentamidine are currently used to treat leishmaniasis. Also, nifurtimox and benznidazole are two drugs currently used to treat Chagas disease. These drugs are associated with toxicity problems such as nephrotoxicity and cardiotoxicity, in addition to resistance problems. As a result, the discovery of novel therapeutic agents has emerged as a top priority and a promising alternative. Overall, there is a need for new and effective treatments for Chagas disease and leishmaniasis, as the current drugs have significant limitations. Peptide-based drugs are attractive due to their high selectiveness, effectiveness, low toxicity, and ease of production. This paper reviews the potential use of peptides in the treatment of Chagas disease and leishmaniasis. Several studies have demonstrated that peptides are effective against Chagas disease and leishmaniasis, suggesting their use in drug therapy for these diseases. Overall, peptides have the potential to be effective therapeutic agents against Chagas disease and leishmaniasis, but more research is needed to fully investigate their potential.

show abstract

Section: Peptide Targeting For Leishmaniasis and Chagas Disease Thera...mentioning

confidence: 99%

The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis

Berhe,

Kumar Cinthakunta Sridhar,

Zerihun

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…It inhibits ATP production in parasite-infected erythrocytes [236]. Finally, Phylloseptin-1, a cationic peptide from the skin secretion of Phyllomedusa azurea, demonstrated high anti-parasitic activity and prevented cross-resistance because of its distinctive chemical structure [237].…”

Section: Anti-microbial Peptidesmentioning

confidence: 99%

The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis

Qvit,

Zerihun,

Kumar

et al. 2023

Preprint

View full text Add to dashboard Cite

Parasitic diseases are among the most serious public health problems in developing countries, causing high mortality and economic burdens. The Trypanosomatidae family includes Leishmania spp. and Trypanosoma cruzi, which cause leishmaniasis and Chagas disease, respectively. Both these parasites are among the major agents of neglected tropical diseases (NTDs). Leishmaniasis is currently the second most widespread vector-borne parasitic disease after malaria. The World Health Organization (WHO) records approximately 0.7-1 million newly diagnosed leishmaniasis cases each year, resulting in approximately 20,000-30,000 deaths. Also, 25 million people worldwide are at risk of Chagas disease and an estimated 6 million people are infected with Trypanosoma cruzi. Despite the similarity of the parasites, the evolution of the disease and the clinical indexes are explicitly different in African, Asian, and American forms of infection. Clinical therapies are associated with drug resistance and side effects. As a result, the discovery of novel therapeutic agents has emerged as a top priority and a promising alternative. Peptide-based drugs are an attractive class of therapeutic agents. They are recognized for being highly selective and effective, as well as safe and well tolerated. Moreover, they are now being explored in the development of novel therapeutics for a variety of health disorders, including oncology, endocrinology, metabolic, cardiovascular, and bone diseases. In addition, they are being explored in tropical diseases such as leishmaniasis and Chagas disease. We will discuss current knowledge regarding the parasite life cycle, signs and symptoms, diagnosis, and treatment options for leishmaniasis and Chagas disease.

show abstract

“…Parasites remain one of the most serious threats to human and veterinary medicine, with current treatment options limited by drug resistance, side-effects and limited efficacy [196]. This has stimulated interest in venoms as a source of novel antiparasitic compounds (for a review see [197]). Most such studies have focused on protozoan parasites, which are responsible for a range of human diseases.…”

Section: Antiparasitic Toxinsmentioning

confidence: 99%

Animal toxins — Nature’s evolutionary-refined toolkit for basic research and drug discovery

Herzig

Cristofori-Armstrong

Israel

et al. 2020

Biochemical Pharmacology

129

View full text Add to dashboard Cite

Venomous animals have evolved toxins that interfere with specific components of their victim's core physiological systems, thereby causing biological dysfunction that aids in prey capture, defense against predators, or other roles such as intraspecific competition. Many animal lineages evolved venom systems independently, highlighting the success of this strategy. Over the course of evolution, toxins with exceptional specificity and high potency for their intended molecular targets have prevailed, making venoms an invaluable and almost inexhaustible source of bioactive molecules, some of which have found use as pharmacological tools, human therapeutics, and bioinsecticides. Current biomedically-focused research on venoms is directed towards their use in delineating the physiological role of toxin molecular targets such as ion channels and receptors, studying or treating human diseases, targeting vectors of human diseases, and treating microbial and parasitic infections. We provide examples of each of these areas of venom research, highlighting the potential that venom molecules hold for basic research and drug development.

show abstract

Venoms as Sources of Novel Anti-parasitic Agents

Cited by 7 publications

References 133 publications

The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis

The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis

The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis

Animal toxins — Nature’s evolutionary-refined toolkit for basic research and drug discovery

Contact Info

Product

Resources

About